These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Adipokines in type 1 diabetes after successful pancreas transplantation: normal visfatin and retinol-binding-protein-4, but increased total adiponectin fasting concentrations. Stadler M; Storka A; Theuer EA; Krebs M; Vojtassakova E; Nowotny P; Pacini G; Kästenbauer T; Luger A; Prager R; Wolzt M; Anderwald C Clin Endocrinol (Oxf); 2010 Jun; 72(6):763-9. PubMed ID: 19769621 [TBL] [Abstract][Full Text] [Related]
4. Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver. Shaker O; El-Shehaby A; Zakaria A; Mostafa N; Talaat S; Katsiki N; Mikhailidis DP Clin Biochem; 2011 Dec; 44(17-18):1457-63. PubMed ID: 21939650 [TBL] [Abstract][Full Text] [Related]
5. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes. Kadoglou NP; Sailer N; Kapelouzou A; Lampropoulos S; Vitta I; Kostakis A; Liapis CD Acta Diabetol; 2012 Aug; 49(4):269-76. PubMed ID: 21748474 [TBL] [Abstract][Full Text] [Related]
6. Adipokines: a novel link between adiposity and carotid plaque vulnerability. Kadoglou NP; Sailer N; Moumtzouoglou A; Kapelouzou A; Gerasimidis T; Kostakis A; Liapis CD Eur J Clin Invest; 2012 Dec; 42(12):1278-86. PubMed ID: 23033969 [TBL] [Abstract][Full Text] [Related]
7. Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance. Hetta HF; Ez-Eldeen ME; Mohamed GA; Gaber MA; ElBadre HM; Ahmed EA; Abdellatief RB; Abd-ElBaky RM; Elkady A; Nafee AM; Zahran AM; Ahmad M Egypt J Immunol; 2018 Jun; 25(2):141-151. PubMed ID: 30600957 [TBL] [Abstract][Full Text] [Related]
8. Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes. Mahmood N; Junejo AM; Jamal Q; Awan R J Pak Med Assoc; 2010 Nov; 60(11):922-6. PubMed ID: 21375196 [TBL] [Abstract][Full Text] [Related]
9. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Laudes M; Oberhauser F; Schulte DM; Freude S; Bilkovski R; Mauer J; Rappl G; Abken H; Hahn M; Schulz O; Krone W Horm Metab Res; 2010 Apr; 42(4):268-73. PubMed ID: 20091460 [TBL] [Abstract][Full Text] [Related]
10. A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. Sucunza N; Barahona MJ; Resmini E; Fernández-Real JM; Ricart W; Farrerons J; Rodríguez Espinosa J; Marin AM; Puig T; Webb SM J Clin Endocrinol Metab; 2009 Oct; 94(10):3889-96. PubMed ID: 19723758 [TBL] [Abstract][Full Text] [Related]
11. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Takebayashi K; Suetsugu M; Wakabayashi S; Aso Y; Inukai T Metabolism; 2007 Apr; 56(4):451-8. PubMed ID: 17378999 [TBL] [Abstract][Full Text] [Related]
13. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Yilmaz MI; Saglam M; Qureshi AR; Carrero JJ; Caglar K; Eyileten T; Sonmez A; Cakir E; Oguz Y; Vural A; Yenicesu M; Stenvinkel P; Lindholm B; Axelsson J Nephrol Dial Transplant; 2008 May; 23(5):1621-7. PubMed ID: 18175782 [TBL] [Abstract][Full Text] [Related]
14. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis. de Boer JF; Bahr MJ; Böker KH; Manns MP; Tietge UJ Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G196-201. PubMed ID: 19074645 [TBL] [Abstract][Full Text] [Related]
15. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy. Eyileten T; Sonmez A; Saglam M; Cakir E; Caglar K; Oguz Y; Vural A; Yenicesu M; Yilmaz MI Nephrology (Carlton); 2010 Mar; 15(2):225-9. PubMed ID: 20470283 [TBL] [Abstract][Full Text] [Related]
16. Visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disorders. Kamińska A; Kopczyńska E; Bieliński M; Borkowska A; Junik R Endokrynol Pol; 2015; 66(2):108-13. PubMed ID: 25931039 [TBL] [Abstract][Full Text] [Related]
17. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Kadoglou NP; Sailer N; Moumtzouoglou A; Kapelouzou A; Tsanikidis H; Vitta I; Karkos C; Karayannacos PE; Gerasimidis T; Liapis CD Exp Clin Endocrinol Diabetes; 2010 Feb; 118(2):75-80. PubMed ID: 19834878 [TBL] [Abstract][Full Text] [Related]
18. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol. Nüsken KD; Petrasch M; Rauh M; Stöhr W; Nüsken E; Schneider H; Dötsch J Nephrol Dial Transplant; 2009 Sep; 24(9):2832-8. PubMed ID: 19389865 [TBL] [Abstract][Full Text] [Related]
19. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Sandeep S; Velmurugan K; Deepa R; Mohan V Metabolism; 2007 Apr; 56(4):565-70. PubMed ID: 17379018 [TBL] [Abstract][Full Text] [Related]
20. Correlation analysis of epicardial adipose tissue thickness, C-reactive protein, interleukin-6, visfatin, juxtaposed with another zinc finger protein 1, and type 2 diabetic macroangiopathy. Gong YY; Peng HY Lipids Health Dis; 2021 Mar; 20(1):25. PubMed ID: 33722242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]